Report Publication Announcement • Mar 13, 2023
Report Publication Announcement
Open in ViewerOpens in native device viewer
PRESS RELEASE
Montpellier, March 13, 2023 - 8:00am – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates with Aonys®, its proprietary buccal nanodroplet active ingredient administration technology is pleased to announce announces its participation in the second European RNA Leaders Congress which will take place in Basel on March 15 and 16.
Medesis Pharma teams will be present to meet with key players in the RNA field and discuss the latest advances in RNA chemistry, clinical updates and potential collaborations in the development of RNA-based therapies.
They will also present a scientific poster at the conference : Aonys® technology - Buccal administration for siRNA systemic delivery describing pharmacokinetic and pharmacological data supporting the potential of the Aonys diseases including its potential application in the genetic treatment of Huntington's disease and in oncology to inhibit the expression of an abnormal or overexpressed gene.
Medesis Pharma's proprietary technology, Aonys®, is an assembly of lipid components that spontaneously self-
structure into a "water-in-oil" microemulsion. Aonys® allows the administration of water-soluble pharmaceutical a ingredients. The product is deposited on the mucosa of the mouth and then transported by lipoproteins and released directly into the cytoplasm of cells throughout the membrane using cell lipoprotein receptors, with crossing of the
Blood-Brain Barrier (BBB). Studies on native siRNAs encapsulated in Aonys® have demonstrated crossing of t
The second edition of RNA Leaders Europe brings together more than 450 professionals from the biotech, pharmaceutical, investment and research science industries.
The congress covers the entire ecosystem and offers conferences, discussions and guests from all RNA disciplines, bringing together the most important decision-makers from RNA Biotechs and large pharmaceutical companies.
For more information:
To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys® technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood-brain barrier (BBB).
This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and certain resistant cancers.
Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.
French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 11 patent families and 72 patents, the result of 19 years of research.
Medesis Pharma shares are listed on Euronext Growth Paris: FR001844464 - ALMDP
For more information: www.medesispharma.com
MEDESIS PHARMA Tessa Olivato Tel: +33 4 67 03 03 96 [email protected]
CALYPTUS Marie Calleux Tel: +33 1 53 65 68 66 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.